The innovation involves a new method for the processing of safe pharmaceutical compositions in the form of embedded powder, composed of Orlistat and pharmaceutically suitable additives that fulfil the applicable consistency requirements. In addition, the invention concerns medicinal compositions of Orlistat, in the form of embedded powder produced pursuant to the present invention process.
Orlistat is a pancreas lipase inhibitor known as tetrahydrolipstatin or THL. The enzymes that hydrolyze dietary fat into glycerol and fatty acid are pounded into the GI tract by Orlistat and prevent lipids from entering the bloodstream. This is why Orlistat is recommended for obesity care in patients with an index of body mass.
The melting point is 44 ° C, attributable to distinct physicochemicals, namely waxy character. orlistat powder manufacturer is considered a technologically taxing and hard-to-handle ingredient in the state-of-the-art and poor chemical stability. Extraction and spheronizing revealed by the International Patent Application, or the production of a solution or homogenic dispersion containing Orlistat under reduction-pressure pressure without boiling, as known in state-of-the-art method of obtaining pharmaceutical compositions consisting of Orlistat, as set forth in International Patent Application. Likewise, pharmaceutical compositions comprising Orlistat are known to use atypical, cost effective and frequently unstable pharmaceutical additives to obtain a product which comply with relevant quality requirements in formulation of the active ingredient rarely used in practise.
Bile acid sequestrants, as stated in international patent applications, are poorly digestible, poorly fermentable, hydrophilic and hydrocolloidal food grades thickeners disclosed in International patent applications and complex surfactants disclosed by International Patents ap international fatty acid or fatty acid salts or blends of fatty fatty acids and fatty acid salts.
About Manufacturer Process
A method for the processing, by mixing the Orlistat and p, of an incapsulated powder consisting of Orlistat and of a pharmaceutically appropriate addition, chosen from a category consisting of a gliding and a disintegrating, or a filler, or of a combination between a disintegrant and a filler.
The invention relates to the method for the processing in form of encapsulated powder of pharmaceutical products consisting of Orlistat and two stages of pharmaceutical appropriate additives. Orletta is combined with pharmaceutically suitable additives chosen from the community in the first stage according to the invention, including a glidant, a disintegrating or a filler or a combination of a decaying and a filler and, as alternative, one or more other pharmaceutical additives to achieve a homogenous powder. The homogeneous powder in the first step is encapsulated in the second step of the process. The invention presents a scheme of the manufacture of pharmaceutical compositions which comprises Orlistat.
The Orlistat manufacturer method of Orlistat pharmaceutical compositions according to the invention involves little atypical application, sometimes causing technical challenges and costly pharmaceutical additives, as the prior art suggests. The invention process makes it possible to use traditional Orlistat like cetilistat powder, commonly used in functional pharmaceutical additives in the Orlistat manufacturer of a pharmaceutical composition, which significantly simplifies its production process and reduces expense.
